NUCLEXIS, created in 2015 (United States), from 5 sister brands and 2214 competing brands. The NUCLEXIS brand is owned by Karyopharm Therapeutics, a company listed in New York. NUCLEXIS belongs to the Biotechnology business sector.

NUCLEXIS is a brand of Karyopharm Therapeutics (KPTI) Share price

International deposit : 2015 Business sector Biotechnology

Share price and profitability of the share Karyopharm Therapeutics (NUCLEXIS)

Buy Karyopharm Therapeutics share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.

Investment simulator :

Amount invested USD 1.12

Portfolio valuation
Karyopharm Therapeutics (NUCLEXIS) over 5 years* USD 0.26

Stock market history Karyopharm Therapeutics (NUCLEXIS)

*non inclusive of dividends, non inclusive of market orders
past performances do not prejudice future performances

Other brands
Karyopharm Therapeutics

See more brands of Karyopharm Therapeutics

Rival brands
NUCLEXIS

NOTABLE LABS
NOTABLE LABS
Roivant
Roivant
Valerio Therapeutics
Valerio Therapeutics
INVERSAGO
INVERSAGO
Terns Pharma
Terns Pharma
Vaxcyte
Vaxcyte
OTHER RIVAL BRANDS

Top Popularity Web

See the full ranking
Desirable brands that generate Pricing Power and therefore stock market performance
Desirable brands that generate Pricing Power and therefore stock market performance

Only companies with a strong brand or unique know-how benefit from this ability to set their prices without impacting demand and thus preserve their margins.

Read more
MORE NEWS